SDHC Gene Pheochromocytoma Type 3 NGS Genetic DNA Test
Comprehensive Genetic Screening for Hereditary Pheochromocytoma Risk
The SDHC Gene Pheochromocytoma Type 3 NGS Genetic DNA Test represents a breakthrough in hereditary cancer risk assessment, specifically targeting mutations associated with familial paraganglioma-pheochromocytoma syndrome. This advanced diagnostic tool utilizes next-generation sequencing (NGS) technology to provide unparalleled accuracy in detecting genetic variations that predispose individuals to developing rare neuroendocrine tumors.
What This Test Measures and Detects
This sophisticated genetic analysis specifically examines the SDHC (succinate dehydrogenase complex subunit C) gene for pathogenic mutations that cause hereditary paraganglioma-pheochromocytoma syndrome type 3. The test identifies:
- Point mutations, deletions, and insertions in the SDHC gene
- Genetic variations affecting mitochondrial complex II function
- Inherited mutations associated with increased tumor susceptibility
- Specific genetic markers for early cancer risk assessment
Who Should Consider This Genetic Test
This comprehensive genetic screening is particularly recommended for individuals experiencing:
- Unexplained or treatment-resistant hypertension
- Episodes of severe headaches, palpitations, and sweating
- Family history of pheochromocytomas or paragangliomas
- Personal history of multiple endocrine neoplasias
- Young-onset adrenal tumors or neuroendocrine cancers
- Genetic counseling recommendations for hereditary cancer risk
Significant Benefits of SDHC Genetic Testing
Undergoing this advanced genetic screening provides numerous advantages:
- Early Risk Identification: Detect genetic predisposition before tumor development
- Personalized Surveillance: Create tailored monitoring protocols based on genetic risk
- Family Planning Guidance: Make informed reproductive decisions
- Proactive Health Management: Implement preventive measures and early interventions
- Comprehensive Genetic Counseling: Receive expert interpretation of results and implications
Understanding Your Test Results
Your genetic test results will be carefully interpreted by our team of certified genetic counselors and oncologists:
- Positive Result: Indicates the presence of a pathogenic SDHC mutation, requiring enhanced surveillance and family member testing
- Negative Result: No detected mutation, though continued monitoring may be recommended based on family history
- Variant of Uncertain Significance: Requires additional family studies and ongoing research correlation
- Comprehensive Report: Includes detailed risk assessment, management recommendations, and family testing guidance
Test Pricing and Availability
| Test Feature | Details |
|---|---|
| Test Name | SDHC Gene Pheochromocytoma Type 3 NGS Genetic DNA Test |
| Discount Price | $500 USD |
| Regular Price | $700 USD |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type | Blood, Extracted DNA, or One Drop Blood on FTA Card |
Nationwide Testing Availability
We proudly offer comprehensive genetic testing services across the United States, with convenient locations in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our state-of-the-art facilities ensure consistent, high-quality testing standards nationwide.
Take Control of Your Genetic Health Today
Don’t wait to understand your hereditary cancer risk. Our expert team of genetic counselors and oncology specialists are ready to guide you through the testing process and help you develop a personalized health management plan based on your genetic profile.
Call or WhatsApp us today at +1(267) 388-9828 to schedule your SDHC Gene Pheochromocytoma Type 3 NGS Genetic DNA Test and take the first step toward proactive cancer prevention and personalized healthcare.
Early detection through genetic testing can significantly impact your long-term health outcomes. Book your appointment now and receive comprehensive genetic counseling as part of your testing experience.
